These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 31085338)

  • 1. Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens.
    Berry E; Miller S; Koch M; Balasubramanian B; Argenbright K; Gupta S
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):647-653. PubMed ID: 31085338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.
    Grobbee EJ; Wisse PHA; Schreuders EH; van Roon A; van Dam L; Zauber AG; Lansdorp-Vogelaar I; Bramer W; Berhane S; Deeks JJ; Steyerberg EW; van Leerdam ME; Spaander MC; Kuipers EJ
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD009276. PubMed ID: 35665911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
    Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification for advanced colorectal neoplasia according to fecal hemoglobin concentration in a colorectal cancer screening program.
    Auge JM; Pellise M; Escudero JM; Hernandez C; Andreu M; Grau J; Buron A; López-Cerón M; Bessa X; Serradesanferm A; Piracés M; Macià F; Guayta R; Filella X; Molina R; Jimenez W; Castells A;
    Gastroenterology; 2014 Sep; 147(3):628-636.e1. PubMed ID: 24937264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
    Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
    Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
    Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Diagnostic Performance of Fecal Immunochemical Tests for Detecting Advanced Neoplasia at Surveillance Colonoscopy.
    Berwald G; Young GP; Cock C; Bampton P; Fraser R; Symonds EL
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):878-885.e2. PubMed ID: 37743036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia.
    Grobbee EJ; Schreuders EH; Hansen BE; Bruno MJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
    Gastroenterology; 2017 Nov; 153(5):1251-1259.e2. PubMed ID: 28760383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis.
    Selby K; Levine EH; Doan C; Gies A; Brenner H; Quesenberry C; Lee JK; Corley DA
    Gastroenterology; 2019 Dec; 157(6):1494-1505. PubMed ID: 31472152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia.
    Kapidzic A; van der Meulen MP; Hol L; van Roon AH; Looman CW; Lansdorp-Vogelaar I; van Ballegooijen M; van Vuuren AJ; Reijerink JC; van Leerdam ME; Kuipers EJ
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1464-71.e4. PubMed ID: 25724706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
    Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Accuracy of a Qualitative Fecal Immunochemical Test Varies With Location of Neoplasia But Not Number of Specimens.
    Wong MC; Ching JY; Chan VC; Lam TY; Shum JP; Luk AK; Wong SS; Ng SC; Ng SS; Wu JC; Chan FK; Sung JJ
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1472-9. PubMed ID: 25724708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal MicroRNA-Based Algorithm Increases Effectiveness of Fecal Immunochemical Test-Based Screening for Colorectal Cancer.
    Duran-Sanchon S; Moreno L; Gómez-Matas J; Augé JM; Serra-Burriel M; Cuatrecasas M; Moreira L; Serradesanferm A; Pozo À; Grau J; Pellisé M; Gironella M; Castells A
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):323-330.e1. PubMed ID: 32113893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).
    Breekveldt ECH; Toes-Zoutendijk E; de Jonge L; Spaander MCW; Dekker E; van Kemenade FJ; van Vuuren AJ; Ramakers CRB; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    BMC Gastroenterol; 2023 Feb; 23(1):45. PubMed ID: 36814185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colonoscopy findings after increasing two-stool faecal immunochemical test (FIT) cut-off: Cross-sectional analysis of the SCREESCO randomized trial.
    Westerberg M; Eriksson J; Metcalfe C; Löwbeer C; Ekbom A; Steele R; Holmberg L; Forsberg A
    J Intern Med; 2024 Aug; 296(2):187-199. PubMed ID: 38845164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.